News
- Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic DermatitisDecember 22, 2020 - 8:40 am
- Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel DiseaseDecember 21, 2020 - 8:39 am
- Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal AntibodyDecember 11, 2020 - 8:04 am
Events
- Event: Kindred Biosciences to Present at Stifel 2020 Virtual Healthcare ConferenceNovember 11, 2020 - 8:38 am
- Event: Kindred Biosciences to Participate in A.G.P. Virtual Healthcare SymposiumNovember 11, 2020 - 8:37 am
- Event: Kindred Biosciences to Announce Third Quarter 2020 Financial ResultsOctober 28, 2020 - 4:10 pm
$4.70
-0.09 (-1.78%)

|
KindredBio proudly supports
Rabies Free Africa
Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (December 22, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs. Atopic […]
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel Disease
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (December 21, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis factor alpha (anti-TNFα antibody) for canine inflammatory bowel disease (IBD). The study was a […]
Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (December 11, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced an agreement granting Elanco Animal Health Incorporated exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus (CPV). As part of the agreement, KindredBio also has a right […]
Kindred Biosciences to Present at Guggenheim Animal Health Summit
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, December 2, 2020 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, Chief Executive Officer, will present on the “How Biologics Will Change Veterinary Practices” panel at the Guggenheim Animal Health Summit at 10am ET on Monday, December 7, 2020. Dr. […]
Kindred Biosciences to Participate in Stifel Virtual Healthcare Conference and A.G.P. Virtual Healthcare Symposium
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, November 11, 2020 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel Virtual Healthcare Conference on November 17 and participate in the A.G.P. Virtual Healthcare Symposium on November 19. Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings. During […]